Nasdaq btai.

BioXcel Therapeutics, Inc. (BTAI) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.9000 +0.0700 (+1.83%) At close: 04:00PM EST 3.9999 +0.10 …

Nasdaq btai. Things To Know About Nasdaq btai.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on November 15, 2023.The analyst firm set a price target for $11.00 expecting BTAI to rise to ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its quarterly earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.42 million.Find the latest Institutional Holdings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations were $-1.29. Operator: Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its ...When is BioXcel Therapeutics's earnings date? BioXcel Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off last year's report dates. Learn more on BTAI's earnings history.The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 dated October 31, 2023.

NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...Find the latest on short interest for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

Alliancebernstein Now Owns 0.10% of BioXcel Therapeutics (BTAI) Feb 9, 2023. NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -1.95 when compared to last closing price of 4.64.Despite this, the company has seen a gain of 14.02% in its stock price over the last five trading days. PennyStocks reported 2023-11-01 that Penny stocks are the wild west of the sBioXcel Therapeutics, Inc. (BTAI) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.9000 +0.0700 (+1.83%) At close: 04:00PM EST 3.9999 +0.10 …View the latest BioXcel Therapeutics Inc. (BTAI) stock price, news, historical charts, analyst ratings and financial information from WSJ.

BioXcel Therapeutics, Inc. Common Stock (BTAI) Nasdaq Listed. DATA AS OF Nov 12, 2021. 0. Add to Watchlist.

14 Aug 2023 ... BioXcel Therapeutics (BTAI 2.37%) stock is plummeting Monday. The clinical ... NASDAQ: BTAI. BioXcel Therapeutics. Today's Change. (2.37%) $0.09.

BTAI BioXcel Therapeutics Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... CT 06511 | www.bioxceltherapeutics.com September 2022 AI-Driven Drug Development in Neuroscience and Immuno-oncology NASDAQ: BTAI This presentation includes "forward-looking state 2022-09-12 - 2 viewsThe FDA-approved Igalmi from BioXcel Therapeutics (NASDAQ:BTAI) for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults has garnered attention.To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.BioXcel Therapeutics (NASDAQ:BTAI), a biopharma company based in Connecticut, leverages AI and machine learning to develop innovative treatments for central nervous system and immuno-oncology ...Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET... NEW HAVEN, Conn., June 18, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI ...

Find the latest Insider Activity data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.OnkosXcel is a subsidiary of BioXcel Therapeutics, Inc. (Nasdaq: BTAI). This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, ...Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM BioXcel Therapeutics (Nasdaq:BTAI) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech BioXcel Therapeutics …

NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -1.95 when compared to last closing price of 4.64.Despite this, the company has seen a gain of 14.02% in its stock price over the last five trading days. PennyStocks reported 2023-11-01 that Penny stocks are the wild west of the sBioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s ...A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. Hagens Berman is a global plaintiffs’ rights complex litigation law firm focusing on corporate accountability ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) dropped 21.2% to settle at $27.21 after Goldman Sachs downgraded the stock from Buy to Sell and lowered its price target from $55 to $24.NEW HAVEN, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...Jun 2, 2023 · Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 586.04% Upside. As of ...

Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ...

NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

BTAI BTAI AFTER HOURS QUOTE BTAI LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ...Find the latest on short interest for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on November 15, 2023.The analyst firm set a price target for $11.00 expecting BTAI to rise to ...2017. 183. Vimal Mehta. https://www.bioxceltherapeutics.com. BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or ...Alliancebernstein Now Owns 0.10% of BioXcel Therapeutics (BTAI) Feb 9, 2023.Add a comment. 1. Try using get_text () method of the all the navegable string of the find_all () list: strings = [x.get_text () for x in stock_elems] This generator expression will return ( print ()) a list with al the text:Oct 10, 2023 · Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and continue to hold any of those NASDAQ: BTAI shares, also have certain options and should contact ... BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ …BRANFORD, Conn., June 07, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial ...BioXcel Therapeutics, Inc. (BTAI). NASDAQ: BTAI · IEX Real-Time Price · USD.NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...In the last trading session, 7.87 million shares of the BioXcel Therapeutics Inc (NASDAQ:BTAI) were traded, and its beta was 0.87. Most recently the company’s share price was $4.79, and it changed around $0.15 or 3.23% from the last close, which brings the market valuation of the company to $140.20M. BTAI currently trades at a discount to its ...

BioXcel Therapeutics Inc (NASDAQ:BTAI) showed a performance of 51.72% in past 30-days. Number of shares sold short was 5.81 million shares which calculate 1 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $10.50 to the stock, which implies a rise of 58.1% to its current value.The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...NEW HAVEN, Conn., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing ...Instagram:https://instagram. libylive one stocktops stocksnasdaq tngx SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...Nov 6, 2023 · BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ... binary forexdemo trading simulator Discover historical prices for BTAI stock on Yahoo Finance. View daily, weekly or monthly format back to when BioXcel Therapeutics, Inc. stock was issued. ... Nasdaq Futures 15,961.50-47.25 (-0.30 ...Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ... dia dividend yield Nov 30, 2023 · Philadelphia, Pennsylvania--(Newsfile Corp. - November 29, 2023) - A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain ... Find the latest Earnings Report Date for TG Therapeutics, Inc. Common Stock (TGTX) at Nasdaq.com.SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI. NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI). Such investors are …